Advantage Alpha Capital Partners LP Protagonist Therapeutics, Inc Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 11,336 shares of PTGX stock, worth $441,650. This represents 0.12% of its overall portfolio holdings.
Number of Shares
11,336Holding current value
$441,650% of portfolio
0.12%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
248Shares Held
56.7MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$228 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$224 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$211 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$164 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$124 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.91B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...